VNDA
Vanda Pharmaceuticals Inc.
VNDA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
VNDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
VNDA's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
VNDA PE Valuation
VNDA has no meaningful PE right now: it lost money over the past year.
VNDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect VNDA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
VNDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.63 | -$3.20 |
| Q2 2026 | -$4.64 | -$3.50 |
| Q1 2026 | -$4.06 | -$3.30 |
| Q4 2025 | -$3.74 | -$3.41 |
| Q3 2025 | -$1.43 | -$1.14 |
| Q2 2025 | -$1.14 | -$0.94 |
| Q1 2025 | -$0.76 | -$0.67 |
| Q4 2024 | -$0.33 | -925% |
VNDA lost $4.63 per share over the past year, a bigger loss than the year before.
VNDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.8M | +24% |
| Q2 2026 | $50.5M | -3.9% |
| Q1 2026 | $51.7M | +3.4% |
| Q4 2025 | $57.2M | +7.6% |
| Q3 2025 | $56.3M | +18% |
| Q2 2025 | $52.6M | +4.2% |
| Q1 2025 | $50M | +5.4% |
| Q4 2024 | $53.2M | +17% |
VNDA's revenue is growing: $70M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -34% | +22 points |
| Q2 2026 | -126% | -53 points |
| Q1 2026 | -97% | -15 points |
| Q4 2025 | -71% | -51 points |
| Q3 2025 | -56% | -33 points |
| Q2 2025 | -73% | -53 points |
| Q1 2025 | -82% | -63 points |
| Q4 2024 | -19% | -3.7 points |
VNDA's operating margin was −34% last quarter, up 22 points from the same quarter a year ago.
VNDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.7M | +$3M |
| Q2 2026 | -$31.3M | -$15.7M |
| Q1 2026 | -$50.4M | -$16.9M |
| Q4 2025 | -$29.5M | -$27.5M |
| Q3 2025 | -$31.8M | -$17M |
| Q2 2025 | -$15.6M | -$8.5M |
| Q1 2025 | -$33.6M | -544% |
| Q4 2024 | -$2M | +$2M |
VNDA has burned cash in eight of the last eight quarters: −$140M over the past year, against −$83M the year before.
VNDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +239K shares |
| 1 year | +2.3% | +1.4M shares |
| 3 years | +5% | +2.9M shares |
| 5 years | +6% | +3.4M shares |
| Available history | +10% | +5.6M shares |
VNDA has 60M diluted shares, up 2.3% from a year ago.
VNDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -80.1x | Net Cash |
| Q2 2023 | -12.2x | Net Cash |
| Q1 2023 | -18.9x | Net Cash |
| Q4 2022 | -14.9x | Net Cash |
| Q3 2022 | -4.5x | Net Cash |
| Q2 2022 | -3.2x | Net Cash |
| Q1 2022 | -2.5x | Net Cash |
| Q4 2021 | -1.2x | Net Cash |
VNDA has more cash than debt.
VNDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.3 | Neutral |
| Stochastic | 11.2 | Oversold |
VNDA's weekly RSI is 31 (neutral) and its Stochastic is 11 (oversold).
VNDA PE vs Healthcare Sector
| Metric | VNDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VNDA has no meaningful PE right now: it lost money over the past year.
VNDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 6.6% below |
| 20 week MA | $4.92 | 20% below |
| 50 week MA | $6.12 | 35% below |
| 100 week MA | $5.37 | 26% below |
| 200 week MA | $5.32 | 26% below |
VNDA is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
VNDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $13.3 | -21% |
| 2021 | $13.3 | $18.0 | +35% |
| 2022 | $18.0 | $6.87 | -62% |
| 2023 | $6.87 | $4.22 | -39% |
| 2024 | $4.22 | $4.81 | +14% |
| 2025 | $4.81 | $7.04 | +46% |
| 2026 YTD | $7.04 | $3.95 | -44% |
VNDA has finished lower in three of the last six years. It's down 44% so far in 2026.